NASDAQ:INMB - INmune Bio Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $10.27 -0.33 (-3.11 %) (As of 04/26/2019 10:28 AM ET)Previous Close$10.60Today's Range$10.15 - $10.8052-Week Range$7.00 - $11.00Volume9,533 shsAverage Volume28,272 shsMarket Capitalization$99.98 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California. Receive INMB News and Ratings via Email Sign-up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INMB Previous Symbol CUSIPN/A CIKN/A Webwww.inmunebio.com Phone858-964-3720Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares9,740,000Market Cap$99.98 million Next Earnings DateN/A OptionableNot Optionable INmune Bio (NASDAQ:INMB) Frequently Asked Questions What is INmune Bio's stock symbol? INmune Bio trades on the NASDAQ under the ticker symbol "INMB." What price target have analysts set for INMB? 1 analysts have issued twelve-month target prices for INmune Bio's stock. Their predictions range from $13.00 to $13.00. On average, they expect INmune Bio's share price to reach $13.00 in the next year. This suggests a possible upside of 26.6% from the stock's current price. View Analyst Price Targets for INmune Bio. What is the consensus analysts' recommendation for INmune Bio? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for INmune Bio. Has INmune Bio been receiving favorable news coverage? Media headlines about INMB stock have trended somewhat positive on Friday, InfoTrie reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. INmune Bio earned a news impact score of 2.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the near future. Who are some of INmune Bio's key competitors? Some companies that are related to INmune Bio include Gritstone Oncology (GRTS), Agenus (AGEN), Solid Biosciences (SLDB), CASI Pharmaceuticals (CASI), Cellular Biomedicine Group (CBMG), LogicBio Therapeutics (LOGC), Harpoon Therapeutics (HARP), Novavax (NVAX), Sutro Biopharma (STRO), Eiger Biopharmaceuticals (EIGR), Gamida Cell (GMDA), ADMA Biologics (ADMA), La Jolla Pharmaceutical (LJPC), Jounce Therapeutics (JNCE) and Compugen (CGEN). What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Cannabis Science (CBIS), Ready Capital (RC), Alteryx (AYX), Otonomy (OTIC) and Wirecard (WDI). Who are INmune Bio's key executives? INmune Bio's management team includes the folowing people: Dr. Raymond J. Tesi, Co-Founder, Pres, CEO & Director (Age 63)Mr. David J. Moss M.B.A., CFO, Treasurer & Sec. (Age 49)Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR, Chief Scientific Officer (Age 57) When does INmune Bio's lock-up period expire? INmune Bio's lock-up period expires on Monday, August 5th. INmune Bio had issued 1,020,560 shares in its initial public offering on February 4th. The total size of the offering was $8,164,480 based on an initial share price of $8.00. After the expiration of INmune Bio's lock-up period, company insiders and major shareholders will be able to sell their shares of the company. How do I buy shares of INmune Bio? Shares of INMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is INmune Bio's stock price today? One share of INMB stock can currently be purchased for approximately $10.2651. How big of a company is INmune Bio? INmune Bio has a market capitalization of $99.98 million. What is INmune Bio's official website? The official website for INmune Bio is http://www.inmunebio.com. How can I contact INmune Bio? INmune Bio's mailing address is 1224 PROSPECT STREET SUITE 150, LA JOLLA CA, 92037. The company can be reached via phone at 858-964-3720 or via email at [email protected] MarketBeat Community Rating for INmune Bio (NASDAQ INMB)Community Ranking: 4.0 out of 5 ( )Outperform Votes: 45 (Vote Outperform)Underperform Votes: 11 (Vote Underperform)Total Votes: 56MarketBeat's community ratings are surveys of what our community members think about INmune Bio and other stocks. Vote "Outperform" if you believe INMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INMB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/26/2019 by MarketBeat.com StaffFeatured Article: What is a balanced fund?